Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oncogene-Driven Metabolic Alterations in Cancer
Hye‐Young Min, Ho‐Young Lee
Biomolecules & Therapeutics (2017) Vol. 26, Iss. 1, pp. 45-56
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Lipid metabolism reprogramming and its potential targets in cancer
Chunming Cheng, Feng Geng, Xiang Cheng, et al.
Cancer Communications (2018) Vol. 38, Iss. 1, pp. 1-14
Open Access | Times Cited: 674
The Double-Edge Sword of Autophagy in Cancer: From Tumor Suppression to Pro-tumor Activity
Rodolfo Chavez-Dominguez, Mario Perez-Medina, José Sullivan López-González, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 248
mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer
Karen Griselda de la Cruz-López, Mariel Esperanza Toledo Guzmán, Elizabeth Sánchez, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 181
Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework
Songyun Zhao, Lanyu Wang, Wei Ding, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 109
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches
Carla Navarro, Ángel Ortega, Raquel Santeliz, et al.
Pharmaceutics (2022) Vol. 14, Iss. 6, pp. 1303-1303
Open Access | Times Cited: 79
Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer
Shahab Fatima, Vineet Kumar, Dhruv Kumar
Medical Oncology (2025) Vol. 42, Iss. 3
Closed Access | Times Cited: 2
Metabolic Reprogramming of Cancer Associated Fibroblasts: The Slavery of Stromal Fibroblasts
Angelica Avagliano, Giuseppina Granato, Maria Rosaria Ruocco, et al.
BioMed Research International (2018) Vol. 2018, pp. 1-12
Open Access | Times Cited: 121
Epigenetic mechanisms and the hallmarks of cancer: an intimate affair.
Nadine Darwiche
PubMed (2020) Vol. 10, Iss. 7, pp. 1954-1978
Closed Access | Times Cited: 91
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
Donghwa Kim, Duc‐Hiep Bach, Yanhua Fan, et al.
Cell Death and Disease (2019) Vol. 10, Iss. 5
Open Access | Times Cited: 87
Landscape of metabolic alterations and treatment strategies in breast cancer
Xiujuan Wu, Xuanni Tan, Yangqiu Bao, et al.
Genes & Diseases (2025), pp. 101521-101521
Open Access | Times Cited: 1
The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies
Yuganthini Vijayanathan, Ivy A. W. Ho
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 669-669
Open Access | Times Cited: 1
E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBPα
Leifeng Chen, Rongfa Yuan, Chongyu Wen, et al.
Oncogene (2020) Vol. 40, Iss. 2, pp. 262-276
Closed Access | Times Cited: 57
The Role of Extracellular Vesicles in Metabolic Reprogramming of the Tumor Microenvironment
Eran Fridman, Lana Ginini, Ziv Gil
Cells (2022) Vol. 11, Iss. 9, pp. 1433-1433
Open Access | Times Cited: 37
An integrative multi-omics analysis based on disulfidptosis-related prognostic signature and distinct subtypes of clear cell renal cell carcinoma
Dong Zhang, Xi Zhang, Zhanpeng Liu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 18
AMPK: The Energy Sensor at the Crossroads of Aging and Cancer
Vasudevarao Penugurti, Rajesh Manne, Ling Bai, et al.
Seminars in Cancer Biology (2024) Vol. 106-107, pp. 15-27
Closed Access | Times Cited: 8
Metabolism and immunity in breast cancer
Deyu Zhang, Xiaojie Xu, Qinong Ye
Frontiers of Medicine (2020) Vol. 15, Iss. 2, pp. 178-207
Closed Access | Times Cited: 49
The multifaceted roles of mitochondria at the crossroads of cell life and death in cancer
Fabrizio Fontana, Patrízia Limonta
Free Radical Biology and Medicine (2021) Vol. 176, pp. 203-221
Closed Access | Times Cited: 33
NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Chufan Cai, Jiayi Tu, Jeronimo Najarro, et al.
Molecular Cancer Research (2024) Vol. 22, Iss. 4, pp. 386-401
Open Access | Times Cited: 5
Phytochemicals Target Multiple Metabolic Pathways in Cancer
Oleg Shuvalov, Yulia Kirdeeva, Alexandra Daks, et al.
Antioxidants (2023) Vol. 12, Iss. 11, pp. 2012-2012
Open Access | Times Cited: 11
Histone Acyl Code in Precision Oncology: Mechanistic Insights from Dietary and Metabolic Factors
Sultan Abda Neja, Wan Mohaiza Dashwood, Roderick H. Dashwood, et al.
Nutrients (2024) Vol. 16, Iss. 3, pp. 396-396
Open Access | Times Cited: 4
Early KRAS oncogenic driver mutations in nonmucinous tissue of congenital pulmonary airway malformations as an indicator of potential malignant behavior
Sergei M. Hermelijn, Janina Wolf, T. Dorine den Toom, et al.
Human Pathology (2020) Vol. 103, pp. 95-106
Open Access | Times Cited: 28
Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine
Na Li, Huanni Li, Ya Wang, et al.
The EPMA Journal (2020) Vol. 11, Iss. 4, pp. 661-694
Open Access | Times Cited: 28
C. elegans as a model for inter-individual variation in metabolism
Bennett W. Fox, Olga Ponomarova, Yong‐Uk Lee, et al.
Nature (2022) Vol. 607, Iss. 7919, pp. 571-577
Open Access | Times Cited: 19
FBXW7 metabolic reprogramming inhibits the development of colon cancer by down-regulating the activity of arginine/mToR pathways
Qing Li, Yan Li, Tong Zhou, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0317294-e0317294
Open Access
Disulfidptosis as a key regulator of glioblastoma progression and immune cell impairment
Yifu Shu, Jing Li
Frontiers in Immunology (2025) Vol. 16
Open Access
Page 1 - Next Page

Scroll to top